Notably, while the WT lymphomas could not be controlled by a clinical dose of cisplatin, eight out of nine mice that had received Polk-deficient lymphomas survived five cycles of cisplatin treatment, and the tumor size reduced to nearly undetectable levels during the treatment phase (Figure 4I, J). The gene discussed is POLK; the disease is neoplasm.